October 8, 2025BMC NeurologyOpen Access

Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Clazosentan significantly reduced the incidence of cerebral vasospasm and related complications in aSAH patients, offering promising outcomes.
Analysis shows that clazosentan treatment led to a 44% lower incidence of vasospasm compared to fasudil and notable reductions in cerebral infarcts.
Inclusion of data from 13 studies (5,728 patients) reinforces the benefits of clazosentan, particularly at higher doses during surgical interventions.
Despite its effectiveness in preventing vasospasm, clazosentan is linked to increased risk of adverse events, requiring careful patient monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Systematic review shows clazosentan reduces cerebral vasospasm and related complications in aSAH, suggesting targeted use in high-risk patients.

Abunada et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review shows clazosentan reduces cerebral vasospasm and related complications in aSAH, suggesting targeted use in high-risk patients.